RxDoctor Payments Data

Todd Wilson, MD

Family Medicine · Winter Garden, FLNPI 1790130862

Payments from drug & device makers

$1,845in general payments, 2019–2025

Across 22 payments — averaging $83.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$786
  • AstraZeneca$250
  • Gilead$229
  • GSK$185
  • Biohaven Pharmaceuticals, Inc.$131
  • Amgen$92
  • plus $171 from 3 others

What the payments were for

  • Food & beverage$1,845100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,845 in reported general payments places this provider in the 70th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$110,586
Medicare patients
243
Services billed
1,678

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$78,448
EliquisApixaban39$46,562
MounjaroTirzepatide36$39,953
Nurtec OdtRimegepant Sulfate12$23,594
JanuviaSitagliptin Phosphate14$22,360
RybelsusSemaglutide12$21,989
FarxigaDapagliflozin Propanediol21$19,485
JardianceEmpagliflozin15$15,818
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$10,750
Atorvastatin Calcium313$3,287
Rosuvastatin Calcium121$1,546
Levothyroxine Sodium158$1,502
Omeprazole83$1,396
Losartan Potassium132$1,352
Albuterol Sulfate HfaAlbuterol Sulfate61$1,252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$786$100,43755 claims
AstraZenecaFarxiga$250$19,48521 claims
Boehringer IngelheimJardiance$23$15,81815 claims
GSKTrelegy Ellipta$185$10,75014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Winter Garden

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →